Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Theravance Bio Ord (TBPH)

Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH PR Newswire - Thu May 7, 9:00AM CDT

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are...

TBPH : 16.64 (+0.91%)
Theravance Bio: Q1 Earnings Snapshot AP - Thu May 7, 7:39AM CDT

Theravance Bio: Q1 Earnings Snapshot

TBPH : 16.64 (+0.91%)
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire - Thu May 7, 7:30AM CDT

DUBLIN , May 7, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of...

TBPH : 16.64 (+0.91%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH PR Newswire - Thu Apr 30, 9:40PM CDT

NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH).  Such investors...

TBPH : 16.64 (+0.91%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH PR Newswire - Thu Apr 16, 9:00AM CDT

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors...

TBPH : 16.64 (+0.91%)
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates PR Newswire - Wed Apr 15, 8:00AM CDT

Theravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS Enrollment

TBPH : 16.64 (+0.91%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH PR Newswire - Thu Apr 9, 9:00AM CDT

NEW YORK , April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH).  Such investors...

TBPH : 16.64 (+0.91%)
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm Business Wire - Thu Apr 2, 7:48PM CDT

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or “the Company”)...

TBPH : 16.64 (+0.91%)
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates PR Newswire - Wed Apr 1, 8:00AM CDT

Theravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS Enrollment

TBPH : 16.64 (+0.91%)
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates PR Newswire - Wed Mar 25, 8:00AM CDT

Theravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS Enrollment

TBPH : 16.64 (+0.91%)

Barchart Exclusives

Mark Cuban Says Everything in the Hospital Could Cost $1 And Insurance Companies Would Still Raise the Prices to ‘Crush People’s Financial Situation’ Barchart - 37 minutes ago
Billionaire Mark Cuban argued that even if hospital services cost just $1, large insurance conglomerates would still drive prices higher, highlighting opportunities for healthcare disruptors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.